# RA Capital Management

> RA Capital Management is a VC fund backing Biotechnology and Health Care. See 521 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Boston, United States
- Total investments: 521
- Last investment: Aug 2026
- Lead investor: 36%
- Last fund: Jul 2025
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/ra-capital-management-llc
- Website: http://www.racap.com

RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.

## Contacts

5 contacts available for RA Capital Management. Shizune tracks 20 team members at RA Capital Management. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/ra-capital-management?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series B | $27M–$152M |
| Series C | $44M–$183M |
| Post-IPO Equity | $35M–$240M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 240 | 46% |
| Health Care | 153 | 29% |
| Therapeutics | 97 | 19% |
| Pharmaceutical | 83 | 16% |
| Medical | 77 | 15% |

52 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 102 | 20% |
| Series C | 65 | 12% |
| Post-IPO Equity | 63 | 12% |
| Series A | 61 | 12% |
| Funding Round | 24 | 5% |

13 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 228 | 44% |
| United Kingdom | 10 | 2% |
| Canada | 6 | 1% |
| China | 5 | 1% |
| Denmark | 4 | 1% |

14 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Cristina Ghenoiu | Principal | 2 | https://shizune.co/investors/profile/cristina-ghenoiu |
| Ajay Yekkirala | VP, Head of Biology | 0 | https://shizune.co/investors/profile/ajay-yekkirala-9184 |
| Andrew Levin | Managing Director | 24 | https://shizune.co/investors/profile/andrew-levin |
| Barbara Herbst | Deputy Chief Compliance Officer | 0 | https://shizune.co/investors/profile/barbara-herbst |
| Dan Marks | Venture Senior Associate | 1 | https://shizune.co/investors/profile/dan-marks |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| LifeMine Therapeutics | Discovering powerful new drugs from eukaryotic microbes by combining Genomics with AI and Synthetic Biology. Founded by Gregory Verdine, PhD, Rick Klausner, MD and WeiQing Zhou, MBA, LifeMine Therapeutics is headquartered in Cambridge, Massachusetts. | $188M | Series E | Aug 06, 2026 |  |
| Plantible Foods | Plantible Foods is a B2B food technology company producing sustainable plant-based protein to optimize the food industry. The company develops a proprietary and vertically integrated agricultural manufacturing platform to allow food companies to innovate while optimizing costs and delivering products with improved taste, texture, health, andenvironmental footprint. | $10M | Venture - Series Unknown | Aug 06, 2026 |  |
| Expedition Therapeutics | Expedition Therapeutics operates as an unincorporated association. | $115M | Series B | Aug 05, 2026 |  |
| Obsidian Therapeutics | Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy to every patient with cancer.The company's next-generation cell and gene therapies with pharmacologic operating systems provide exquisite control of protein activity in cells and create adoptive cell therapies with newfunctions that are under control of the treating physician using simple, safe, orally-active, marketed drugs, enabling patients to improve on the current generation of cell therapies. | $350M | Post-IPO Equity | Aug 04, 2026 |  |
| Processa Pharmaceuticals | Processa Pharmaceuticals operates as a pharmaceutical company. The company focuses on development of drug products that are intended to improve the survival and quality of life for patients who have unmet medical need. | $200M | Post-IPO Equity | Jul 29, 2026 |  |
| Entera Bio | Entera Bio is developing novel oral drugs by utilizing its proprietary cutting edge delivery technology This technology protects large molecules and peptides in the GI tract. Oral drug delivery is the most straight forward and user friendly approach to medical treatment. Entera Bio has key personnel with the relevant know how, experience andnetworks working together to enable rapid development of its products. The company has an experienced management team with more than 50 years of combined drug development experience. | $275M | Post-IPO Equity | Jul 27, 2026 |  |
| Freenome | Freenome is a biotechnology company developing blood tests for early cancer detection to improve access to routine screening. | $240M | Post-IPO Equity | Jul 20, 2026 |  |
| Agenus | Agenus develops and commercializes immunotherapies and vaccines for cancer and infectious diseases. The company's treatment aims to stimulate the immune system to recognize and fight cancer cells. Its goal is to treat cancers with novel combinations utilizing its unique portfolio of checkpoint antibodies, tumor microenvironment modifiers,vaccines, and adjuvants. In addition to a broad portfolio, the company has an accomplished team of scientists, novel technology platforms, and fully-integrated end-to-end capabilities from discovery to GMP manufacturing.It was established in 1994 and is headquartered in Lexington, Massachusetts. | $85M | Post-IPO Debt | Jul 13, 2026 |  |
| Celea Therapeutics | Celea Therapeutics develops drug therapies for serious respiratory and fibrotic lung diseases. The company focuses on idiopathic pulmonary fibrosis (IPF) and is advancing deupirfenidone (LYT-100), an oral investigational therapy. Deupirfenidone is being studied as a potential new standard of care for IPF, with completed Phase 2b data and a pivotalPhase 3 trial planned. Celea also runs an open-label extension study to assess long-term outcomes and collaborates with clinicians and patient groups on IPF patient experience research. Celea is a wholly-owned subsidiary of PureTech Health plc. | $180M | Private Equity | Jul 02, 2026 |  |
| Ollin Biosciences | Ollin Biosciences operates as a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases. | $330M | Series B | Jun 24, 2026 |  |

10 of 521 investments shown.

## Co-investors
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 87 deals together
- [Janus Henderson Investors](https://shizune.co/investors/profile/janus-henderson-investors) — VC Fund, 78 deals together
- [Perceptive Advisors](https://shizune.co/investors/profile/perceptive-advisors) — VC Fund, 65 deals together
- [Logos Capital](https://shizune.co/investors/profile/logos-capital) — VC Fund, 58 deals together
- [Surveyor Capital](https://shizune.co/investors/profile/surveyor-capital) — VC Fund, 57 deals together
- [Biotechnology Value Fund](https://shizune.co/investors/profile/biotechnology-value-fund) — VC Fund, 49 deals together

## Similar investors

### Similar industry
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [Vaekstfonden](https://shizune.co/investors/profile/v%C3%A6kstfonden) — VC Fund
- [PSV](https://shizune.co/investors/profile/preseed-innovation) — VC Fund
- [Seed Capital](https://shizune.co/investors/profile/seed-capital) — VC Fund

## Featured in investor lists
- [Health Care Investors](https://shizune.co/investors/health-care-investors)
- [Health Care VC Funds](https://shizune.co/investors/health-care-vc-funds)
- [Biotech Investors](https://shizune.co/investors/biotech-investors)
- [Biotech VC Funds](https://shizune.co/investors/biotech-vc-funds)
- [Biotechnology Investors](https://shizune.co/investors/biotechnology-investors)
- [Biotechnology VC Funds](https://shizune.co/investors/biotechnology-vc-funds)

## FAQ

### What does RA Capital Management invest in?

RA Capital Management invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series C stage. Most of the 521 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is RA Capital Management's check size?

RA Capital Management typically joins rounds of $27M–$152M at Series B, $44M–$183M at Series C and $35M–$240M at Post-IPO Equity. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds RA Capital Management participates in.

### How do I contact RA Capital Management?

Public channels for RA Capital Management include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at RA Capital Management?

The team at RA Capital Management includes Cristina Ghenoiu (Principal), Ajay Yekkirala (VP, Head of Biology) and Andrew Levin (Managing Director), among 20 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co